The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The trial's primary analysis indicated an 83.7% efficacy ... decision made after consulting with a healthcare provider. The ...

Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...

FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

I t’s vaccination season, which for most people means getting immunized for flu and COVID-19 (and RSV for infants, pregnant ...